2024-514341-10-00招募中1 期
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 64
- 试验地点
- 8
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CTIS Point of Contact
Scientific
Janssen Cilag International
研究点 (8)
Loading locations...
相似试验
已完成
1 期
A first in human single dose escalation study to investigate the safety, tolerability, pharmacokinetics, and pharmcodynamics of BAY 3389934 compared with placebo.2022-502866-25-00Bayer AG86
招募中
1/2 期
A phase I dose-escalation study testing the feasibility and the tolerance of infusion of a third party suicide gene-transduced anti-HLA-DPB1*0401 cytotoxic T cell clone in patients with HLA-DPB1*0401 positive hematologic malignancies and receiving an allotransplant from HLA-DPB1*0401 negative donors2024-515504-39-00Centre Hospitalier Universitaire De Nantes6
招募中
2 期
GEN1047 for Solid Tumors - First in Human (FIH) Trial2024-510722-10-00Genmab A/S268
招募中
1 期
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)NCT07282847AskBio Inc12
招募中
1 期
A first-in-human dose escalation and expansion study with the SIRPα-directed monoclonal antibody BYON4228 alone and in combination with rituximab to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy in patients with relapsed/refractory CD20 positive B-cell Non-Hodgkin’s Lymphoma (NHL)2024-512390-27-00Byondis B.V.66